Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048399 · ClinicalTrials.gov registry record · Phase 1
Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H
A Phase 1 study, sponsored by Baylor College of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00048399 is a Phase 1 study that was terminated before completion, run by Baylor College of Medicine. The registered enrollment target is 40 participants.
The verdict
NCT00048399, a Phase 1 study, was terminated before completion, sponsored by Baylor College of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
To assess the safety, feasibility, and rate of donor engraftment for patients with primary or secondary engraftment failure after treatment with fludarabine and CAMPATH 1H used as a preparative regimen for HLA-identical sibling blood stem cell transplantation (SCT). To assess the safety, feasibility, and rate of donor engraftment for patients with primary or secondary engraftment failure after treatment with fludarabine and CAMPATH 1H as a preparative regimen for matched unrelated or single antigen mismatched family donor marrow transplantation.
Interventions
- DRUG Fludarabine
- PROCEDURE Stem Cell Transplantation
- DRUG CAMPATH 1H
- DRUG FK506
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2000-12 |
| Est. Completion | 2003-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048399
The ClinicalTrials.gov registry entry for NCT00048399 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fludarabine is the first listed.
NCT00048399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00048399 about?
NCT00048399 is a clinical study titled "Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H". To assess the safety, feasibility, and rate of donor engraftment for patients with primary or secondary engraftment failure after treatment with fludarabine and CAMPATH 1H used as a preparative regimen for HLA-identical sibling blood stem cell transplantation (SCT). To assess the safety, feasibilit...
What is the current status of trial NCT00048399?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2000-12. Estimated completion is 2003-10-31.
What interventions are being tested in trial NCT00048399?
The interventions under investigation include: Fludarabine (DRUG), Stem Cell Transplantation (PROCEDURE), CAMPATH 1H (DRUG), FK506 (DRUG).
Who is sponsoring clinical trial NCT00048399?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.